| Ahmed M Safa, MD | |
|
85 Herrick St, Beverly, MA 01915-1777 | |
| (978) 927-6850 | |
| Not Available |
| Full Name | Ahmed M Safa |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 15 Years |
| Location | 85 Herrick St, Beverly, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275970501 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 283554 (Maryland) | Secondary |
| 207RH0003X | Internal Medicine - Hematology & Oncology | 283554 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Visiting Nurse Hospice | Wakefield, MA | Hospice |
| Northeast Hospital Corporation | Beverly, MA | Hospital |
| Lahey Hospital & Medical Center, Burlington | Burlington, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northeast Medical Practice Inc | 2365405024 | 188 |
News Archive
Progenika Biopharma S.A., a pioneer in the field of personalized medicine, announced today that it has obtained the CE Mark allowing the sale in Europe of its LPLchip(R), the first DNA chip to detect mutations in the lipoprotein lipase (LPL) gene.
Bristol-Myers Squibb Company and Pfizer report that preliminary results from the Phase 3 AVERROES clinical trial of the investigational drug apixaban compared with acetylsalicylic acid (ASA, or aspirin) in patients with atrial fibrillation expected to be or demonstrated to be unsuitable for warfarin therapy will be presented at the European Society of Cardiology Congress 2010. The results will be presented during the "Hot Line" session on August 31, 2010, in Stockholm, Sweden.
Cerus Corporation announced today that it has initiated patient enrollment in two European Phase III clinical trials for the INTERCEPT System for red blood cells.
Researchers at Zucker Hillside Hospital's Recognition and Prevention (RAP) Program who have worked with teenagers at risk for serious mental illness for the past decade are now studying the effectiveness of Omega 3 fatty acids (fish oil) for treating psychiatric symptoms.
› Verified 8 days ago
| Entity Name | Northeast Medical Practice Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235147760 PECOS PAC ID: 2365405024 Enrollment ID: O20050111000265 |
News Archive
Progenika Biopharma S.A., a pioneer in the field of personalized medicine, announced today that it has obtained the CE Mark allowing the sale in Europe of its LPLchip(R), the first DNA chip to detect mutations in the lipoprotein lipase (LPL) gene.
Bristol-Myers Squibb Company and Pfizer report that preliminary results from the Phase 3 AVERROES clinical trial of the investigational drug apixaban compared with acetylsalicylic acid (ASA, or aspirin) in patients with atrial fibrillation expected to be or demonstrated to be unsuitable for warfarin therapy will be presented at the European Society of Cardiology Congress 2010. The results will be presented during the "Hot Line" session on August 31, 2010, in Stockholm, Sweden.
Cerus Corporation announced today that it has initiated patient enrollment in two European Phase III clinical trials for the INTERCEPT System for red blood cells.
Researchers at Zucker Hillside Hospital's Recognition and Prevention (RAP) Program who have worked with teenagers at risk for serious mental illness for the past decade are now studying the effectiveness of Omega 3 fatty acids (fish oil) for treating psychiatric symptoms.
› Verified 8 days ago
| Entity Name | Winchester Lahey Inpatient Specialists Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144770629 PECOS PAC ID: 6608150149 Enrollment ID: O20170301002194 |
News Archive
Progenika Biopharma S.A., a pioneer in the field of personalized medicine, announced today that it has obtained the CE Mark allowing the sale in Europe of its LPLchip(R), the first DNA chip to detect mutations in the lipoprotein lipase (LPL) gene.
Bristol-Myers Squibb Company and Pfizer report that preliminary results from the Phase 3 AVERROES clinical trial of the investigational drug apixaban compared with acetylsalicylic acid (ASA, or aspirin) in patients with atrial fibrillation expected to be or demonstrated to be unsuitable for warfarin therapy will be presented at the European Society of Cardiology Congress 2010. The results will be presented during the "Hot Line" session on August 31, 2010, in Stockholm, Sweden.
Cerus Corporation announced today that it has initiated patient enrollment in two European Phase III clinical trials for the INTERCEPT System for red blood cells.
Researchers at Zucker Hillside Hospital's Recognition and Prevention (RAP) Program who have worked with teenagers at risk for serious mental illness for the past decade are now studying the effectiveness of Omega 3 fatty acids (fish oil) for treating psychiatric symptoms.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ahmed M Safa, MD 85 Herrick St, Beverly, MA 01915-1777 Ph: (978) 927-6850 | Ahmed M Safa, MD 85 Herrick St, Beverly, MA 01915-1777 Ph: (978) 927-6850 |
News Archive
Progenika Biopharma S.A., a pioneer in the field of personalized medicine, announced today that it has obtained the CE Mark allowing the sale in Europe of its LPLchip(R), the first DNA chip to detect mutations in the lipoprotein lipase (LPL) gene.
Bristol-Myers Squibb Company and Pfizer report that preliminary results from the Phase 3 AVERROES clinical trial of the investigational drug apixaban compared with acetylsalicylic acid (ASA, or aspirin) in patients with atrial fibrillation expected to be or demonstrated to be unsuitable for warfarin therapy will be presented at the European Society of Cardiology Congress 2010. The results will be presented during the "Hot Line" session on August 31, 2010, in Stockholm, Sweden.
Cerus Corporation announced today that it has initiated patient enrollment in two European Phase III clinical trials for the INTERCEPT System for red blood cells.
Researchers at Zucker Hillside Hospital's Recognition and Prevention (RAP) Program who have worked with teenagers at risk for serious mental illness for the past decade are now studying the effectiveness of Omega 3 fatty acids (fish oil) for treating psychiatric symptoms.
› Verified 8 days ago
Ronald Newman, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 85 Herrick St, Lahey At Beverly Hospital, Beverly, MA 01915 Phone: 978-922-3000 | |
Joel W Shelkrot, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: Beverly Hospital, Herrick Street, Beverly, MA 01915 Phone: 978-922-3000 | |
Dr. Ariadne Stephanie Scott Iriarte, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 85 Herrick St, Beverly, MA 01915 Phone: 978-922-3000 | |
Pierre Abou-ezzi, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 100 Cummings Center, Suite 126q, Beverly, MA 01915 Phone: 978-524-8181 Fax: 978-524-9868 | |
Thuy Le, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 85 Herrick St, Beverly, MA 01915 Phone: 978-922-3000 Fax: 978-524-6088 | |
Dr. David Goldberg, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: Lahey Cardiology, Beverly, 75 Herrick Street Suite 206, Beverly, MA 01915 Phone: 978-927-8400 Fax: 978-922-1452 | |
Dorina Omari, M.D. Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 100 Cummings Ctr, Suite 166 D, Beverly, MA 01915 Phone: 978-712-3360 Fax: 978-712-3392 |